Pancreatic Cancer Research

ResearcherCanadian Cancer Trials GroupActive in the last 2 years

Yves Rinaldi

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 8 November 2026

Matched on OpenAlex author ID A5086706783. Sources: OpenAlex.

Their work

Papers
8
Trials
0
Grants
0
Labs led
0
Collaborators
34
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 2 papers · 2025: none · 2026: 2 papers

Papers 8

  1. Sequential alternation of nal-IRI/5-FU and gemcitabine/nab-paclitaxel versus nal-IRI/5-FU versus gemcitabine/nab-paclitaxel in first-line metastatic pancreatic… Co-author DOI 10.1016/j.eclinm.2026.103998↗
  2. Emergency integrative supportive care program for frail patients with advanced pancreatic cancer: A prospective GERCOR ARCAD study Co-author DOI 10.64898/2026.06.18.26355998↗
  3. Clinico-biological factors predicting the benefit of the LV5FU2 maintenance strategy as a first-line therapy in patients with metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyae079↗
  4. Gemcitabine and Paclitaxel Versus Gemcitabine Alone After 5-Fluorouracil, Oxaliplatin, and Irinotecan in Metastatic Pancreatic Adenocarcinoma: A Randomized Pha… Co-author DOI 10.1200/jco.23.00795↗
  5. Five-Year Outcomes of FOLFIRINOX vs Gemcitabine as Adjuvant Therapy for Pancreatic Cancer: A Randomized Clinical Trial. Co-author DOI 10.1001/jamaoncol.2022.3829↗
  6. Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Co-author DOI 10.1038/s41416-021-01624-2↗
  7. Randomized Phase II Trial Evaluating Two Sequential Treatments in First Line of Metastatic Pancreatic Cancer: Results of the PANOPTIMOX-PRODIGE 35 Trial. Co-author DOI 10.1200/jco.20.03329↗
  8. Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma… Co-author DOI 10.1016/j.ejca.2020.05.018↗

Closest collaborators

The 25 strongest of 34 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jean‐Baptiste Bachet · 5 shared papers, 2021–2026 · strength 0.83
  2. Cindy Neuzillet · 2 shared papers, 2024–2026 · strength 0.37
  3. Christelle de la Fouchardière · 2 shared papers, 2024–2026 · strength 0.37
  4. Julien Taı̈eb · 2 shared papers, 2022–2026 · strength 0.35
  5. Côme Lepage · 2 shared papers, 2021–2026 · strength 0.33
  6. David Malka · 2 shared papers, 2021–2024 · strength 0.26
  7. Nicolas Williet · 2 shared papers, 2021–2024 · strength 0.26
  8. Olivier Bouché · 2 shared papers, 2021–2024 · strength 0.26
  9. Laëtitia Dahan · 2 shared papers, 2021–2022 · strength 0.23
  10. Jean–Marc Phelip · 2 shared papers, 2021–2022 · strength 0.23
  11. Carole Vitellius · 1 shared paper, 2026 · strength 0.22
  12. Frédéric Di Fiore · 1 shared paper, 2026 · strength 0.22
  13. Anna Pellat · 1 shared paper, 2026 · strength 0.22
  14. Simon Pernot · 1 shared paper, 2026 · strength 0.22
  15. David Tougeron · 1 shared paper, 2026 · strength 0.22
  16. Déwi Vernerey · 1 shared paper, 2026 · strength 0.22
  17. Benoı̂t Rousseau · 1 shared paper, 2026 · strength 0.22
  18. Jerome F. Cros · 1 shared paper, 2026 · strength 0.22
  19. Christophe Tournigand · 1 shared paper, 2026 · strength 0.22
  20. Marc Hilmi · 1 shared paper, 2026 · strength 0.22
  21. Isabelle Trouilloud · 1 shared paper, 2026 · strength 0.22
  22. Thierry André · 1 shared paper, 2026 · strength 0.22
  23. Aurélien Lambert · 1 shared paper, 2026 · strength 0.22
  24. Christophe Louvet · 1 shared paper, 2026 · strength 0.22
  25. Pascal R. Hammel · 1 shared paper, 2026 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.